BTAI
$47.46
Bioxcel Therapeutics
$2.00
4.40%
BTAI
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.80)
Revenue:  $0.00 Mil
Thursday
Nov 12
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BTAI reports earnings?
Beat
Meet
Miss

Where is BTAI's stock price going from here?
Up
Flat
Down
Stock chart of BTAI
Analysts
Summary of analysts' recommendations for BTAI
Score
Grade
Pivots
Resistance
$50.54
$48.78
$47.12

$45.36

Support
$43.70
$41.94
$40.28
Tweet
Growth
Description
BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.